Why the study?
Although upgrading to cardiac resynchronization therapy improves outcomes in pacing-induced cardiomyopathy, predictors of CRT response remain unclear.
Does baseline Cornell product predict echocardiographic response to CRT upgrade in patients with pacing-induced cardiomyopathy?
Does baseline Cornell product predict echocardiographic response to CRT upgrade in patients with pacing-induced cardiomyopathy?
Baseline Cornell product and absence of atrial fibrillation are independent predictors of favorable echocardiographic response to CRT upgrade in patients with pacing-induced cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Absence of AF was associated with CRT response; hypothesis-generating and requires prospective validation.
Background Pacing-induced cardiomyopathy (PICM) can lead to heart failure due to right ventricular pacing dependency. Although upgrading to cardiac resynchronization therapy (CRT) has been reported to improve outcomes, predictors of CRT response in PICM remain unclear. Purpose To investigate whether the Cornell product can predict responders to CRT upgrade in patients with PICM. Methods Among 931 patients who underwent device implantation between 2017 and 2023 at two hospitals, 57 patients underwent CRT upgrade for PICM. Of these, 46 patients with available follow-up data were included in the analysis. CRT responder was defined as a ≥15% reduction in left ventricular end-systolic volume (LVESV) on transthoracic echocardiography. Cornell voltage was defined as RaVL + SV3 (mV), and Cornell product was calculated as Cornell voltage × QRS duration (ms·mV). Results The study population included 73.9% males, with a mean age of 68.0 ± 9.3 years. Pre-upgrade parameters were as follows: left ventricular ejection fraction (LVEF) 31.6 ± 12.4%, LVESV 131.1 ± 54.1 mL, paced QRS duration 175.7 ± 26.9ms, Cornell voltage 3.03 ± 1.12 mV, and Cornell product 539.1 ± 239.9 ms·mV. Twenty-seven patients (58.7%) were classified as responders. On univariate analysis, atrial fibrillation (p=0.035), paced QRS duration (p=0.0495), Cornell voltage (p=0.027), and Cornell product (p=0.014) were significantly associated with response. Multivariate analysis identified the absence of atrial fibrillation (OR 9.206, 95% CI 1.829–75.481, p=0.006) and higher Cornell product per 100 ms·mV increase (OR 1.624, 95% CI 1.061–2.485, p=0.030) as independent predictors of CRT response. Conclusions In patients with PICM undergoing CRT upgrade, baseline Cornell product may serve as an independent predictor of favorable response.
No takes yet. Share an insight, caveat, or question.
Yokomori et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: